Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, Fasciola hepatica - PubMed

Affiliations

• PMID: 24566472
• DOI: 10.1016/j.bbapap.2014.02.008

Free article

Biochemical characterisation of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the liver fluke, Fasciola hepatica

Veronika L Zinsser et al. Biochim Biophys Acta. 2014 Apr.

Free article

Abstract

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyses one of the two steps in glycolysis which generate the reduced coenzyme NADH. This reaction precedes the two ATP generating steps. Thus, inhibition of GAPDH will lead to substantially reduced energy generation. Consequently, there has been considerable interest in developing GAPDH inhibitors as anti-cancer and anti-parasitic agents. Here, we describe the biochemical characterisation of GAPDH from the common liver fluke Fasciola hepatica (FhGAPDH). The primary sequence of FhGAPDH is similar to that from other trematodes and the predicted structure shows high similarity to those from other animals including the mammalian hosts. FhGAPDH lacks a binding pocket which has been exploited in the design of novel antitrypanosomal compounds. The protein can be expressed in, and purified from Escherichia coli; the recombinant protein was active and showed no cooperativity towards glyceraldehyde 3-phosphate as a substrate. In the absence of ligands, FhGAPDH was a mixture of homodimers and tetramers, as judged by protein-protein crosslinking and analytical gel filtration. The addition of either NAD⁺ or glyceraldehyde 3-phosphate shifted this equilibrium towards a compact dimer. Thermal scanning fluorimetry demonstrated that this form was considerably more stable than the unliganded one. These responses to ligand binding differ from those seen in mammalian enzymes. These differences could be exploited in the discovery of reagents which selectively disrupt the function of FhGAPDH.

Keywords: Drug target; G3PDH; Glycolytic enzyme; Neglected tropical disease; Trematode; Vaccine target.

Similar articles

• Identification and characterization of glyceraldehyde 3-phosphate dehydrogenase from Fasciola gigantica.

  Chetri PB, Shukla R, Tripathi T. Chetri PB, et al. Parasitol Res. 2019 Mar;118(3):861-872. doi: 10.1007/s00436-019-06225-w. Epub 2019 Jan 31. Parasitol Res. 2019. PMID: 30706165

• Biochemical characterisation of triose phosphate isomerase from the liver fluke Fasciola hepatica.

  Zinsser VL, Hoey EM, Trudgett A, Timson DJ. Zinsser VL, et al. Biochimie. 2013 Nov;95(11):2182-9. doi: 10.1016/j.biochi.2013.08.014. Epub 2013 Aug 20. Biochimie. 2013. PMID: 23973283

• Characterization and structure of glyceraldehyde-3-phosphate dehydrogenase type 1 from Escherichia coli.

  Zhang L, Liu MR, Yao YC, Bostrom IK, Wang YD, Chen AQ, Li JX, Gu SH, Ji CN. Zhang L, et al. Acta Crystallogr F Struct Biol Commun. 2020 Sep 1;76(Pt 9):406-413. doi: 10.1107/S2053230X20010067. Epub 2020 Aug 19. Acta Crystallogr F Struct Biol Commun. 2020. PMID: 32880588 Free PMC article.

• Study of the properties of phosphorylating D-glyceraldehyde-3-phosphate dehydrogenase.

  Nagradova NK. Nagradova NK. Biochemistry (Mosc). 2001 Oct;66(10):1067-76. doi: 10.1023/a:1012472627801. Biochemistry (Mosc). 2001. PMID: 11736628 Review.

• Protein thiol modification of glyceraldehyde-3-phosphate dehydrogenase as a target for nitric oxide signaling.

  Brüne B, Lapetina EG. Brüne B, et al. Genet Eng (N Y). 1995;17:149-64. Genet Eng (N Y). 1995. PMID: 7540026 Review.

Cited by

• Identification and characterization of glyceraldehyde 3-phosphate dehydrogenase from Fasciola gigantica.

  Chetri PB, Shukla R, Tripathi T. Chetri PB, et al. Parasitol Res. 2019 Mar;118(3):861-872. doi: 10.1007/s00436-019-06225-w. Epub 2019 Jan 31. Parasitol Res. 2019. PMID: 30706165

• Schistosoma mansoni glyceraldehyde-3-phosphate dehydrogenase enhances formation of the blood-clot lysis protein plasmin.

  Pirovich DB, Da'dara AA, Skelly PJ. Pirovich DB, et al. Biol Open. 2020 Mar 24;9(3):bio050385. doi: 10.1242/bio.050385. Biol Open. 2020. PMID: 32098782 Free PMC article.

• Therapeutic and vaccinomic potential of moonlighting proteins for the discovery and design of drugs and vaccines against schistosomiasis.

  Motlhatlhedi K, Pilusa NB, Ndaba T, George M, Masamba P, Kappo AP. Motlhatlhedi K, et al. Am J Transl Res. 2024 Sep 15;16(9):4279-4300. doi: 10.62347/BXRT7210. eCollection 2024. Am J Transl Res. 2024. PMID: 39398578 Free PMC article. Review.

• Proteomics and bioinformatics analysis of Fasciola hepatica somatic proteome in different growth phases.

  Xu J, Wu L, Sun Y, Wei Y, Zheng L, Zhang J, Pang Z, Yang Y, Lu Y. Xu J, et al. Parasitol Res. 2020 Sep;119(9):2837-2850. doi: 10.1007/s00436-020-06833-x. Epub 2020 Aug 5. Parasitol Res. 2020. PMID: 32757109 Free PMC article.

• UDP-galactose 4'-epimerase from the liver fluke, Fasciola hepatica: biochemical characterization of the enzyme and identification of inhibitors.

  Zinsser VL, Lindert S, Banford S, Hoey EM, Trudgett A, Timson DJ. Zinsser VL, et al. Parasitology. 2015 Mar;142(3):463-72. doi: 10.1017/S003118201400136X. Epub 2014 Aug 15. Parasitology. 2015. PMID: 25124392 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • CORE
  • Elsevier Science

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program